Abstract: The present invention relates to a novel hybrid/fusion protein derived from the CS protein of Plasmodium vivax (P. vivax), methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, for example those caused by P. vivax, compositions/vaccines containing the protein or antibodies against the protein such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. The invention also extends to lipoprotein particles of said hybrid protein and formulations/vaccines comprising the same and use thereof. In particular it relates to an immunogenic hybrid fusion protein comprising: a. at least one repeat unit derived from the repeating region of a type I circumsporozoite protein of P. vivax, b. at least one repeat unit derived from the repeating region of a type II circumsporozoite protein of P. vivax, and surface antigen S derived from Hepatitis B virus, or a fragment thereof.

Abstract: The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. In particular it relates to an immunogenic protein particle comprising the following monomers: a. a fusion protein comprising sequences derived from a CS protein of P. vivax and the S antigen of Hepatitis B (CSV-S), and b. a fusion protein comprising sequences derived from CS protein of P. falciparum and S antigen of Hepatitis B (RTS), and c. optionally the S antigen derived from Hepatitis B.

Abstract: There is provided, inter alia, a method for the prophylaxis of productive malaria infection in travelers to endemic regions comprising the administration of suitable amounts of a formulation comprising a Plasmodium antigen or an immunogenic fragment or derivative thereof and an adjuvant, comprising a lipid A derivative and a saponin in a liposome formulation.

Abstract: The invention relates to use of an antigen derived from the circumsporozoite protein (CS) protein of Plasmodium falciparum which is expressed at the pre-erythrocytic stage of malarial infection in combination with a pharmaceutically acceptable adjuvant, in the manufacture of a medicament for vaccinating infants against malaria.

Abstract: The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. Furthermore, particles with the specific ratio can be prepared by employing yeast, Saccharomyces cerevisiae or Pichia pastoris. In particular it relates to an immunogenic protein particle comprising the following monomers: a. a fusion protein comprising sequences derived from a CS protein of P. vivax and the S antigen of Hepatitis B (CSV-S), and b. S antigen derived from Hepatitis B virus, and characterized in that the ratio of S to CSV-S is in the range 0.1 to 1. Suitably, the ratio of S to CSV-S is in the range 0.19 to 0.30 or 0.68 to 0.80.

Abstract: Aspects of the present disclosure involve systems, methods, products, and the like, for a filtration system that incorporates a plurality of back-washable filter cells into a cell manifold for filtering contaminants from a fluid. Each of the filter cells of the filter system are a small fluid filtration unit that includes a contained granular filtration media that can independently perform regenerative filtration functions of filtration and backwash. In one particular embodiment, the cell manifold is a cylindrical-shaped manifold into which the plurality of filter cells are housed. During operation, the filter system passes fluid through one or more of the filter cells of the cell manifold during a filter cycle, and distributes fluid for backwashing the cells in a backwash cycle. The filter cells of the filtration system utilize a counter-point compaction of the granular media that radially displaces outwardly the granular media.

Abstract: A motor with associated load sensor is connected to a circulation pump of a swimming pool circulation system. The load sensor performs the function of a safety vacuum release system by detecting underload of the motor. Underload is now discovered to be reliably indicative of blockage on the intake side of a circulation pump. A switch controlled by the load sensor shuts off the motor in response to a suitable underload. Vacuum on the intake side of the circulation pump neutralizes, thereby freeing a person or object blocking the suction line.

Abstract: The invention pertains to methods for protecting against malaria infection by vaccination. The method of the invention involves priming an anti-malaria immune response with a DNA-based vaccine and boosting that response with a protein-based a vaccine. The method of the invention also relates to broadening the resulting immune response by boosting with a protein-based vaccine.

Abstract: A Safety Vacuum Release System (SVRS) which incorporates a water flow-rate sensor in electrical communication with the electric motor which powers a swimming pool pump at an aquatic facility. When the flow of water drops to a rate indicative of a flow blockage at a suction outlet fitting within the pool, the SVRS shuts down the electric pump motor to release a suction entrapped bather. In one embodiment, the flow-rate sensor can be a transit time or a Doppler unit which features a non-invasive, clamp-on installation onto the circulation pipe. The SVRS can display the real-time rate of flow of the circulation system, the real-time turnover rate of the swimming pool, and signal the operator when it is time to clean the pool filter. The SVRS can also maintain the optimum flow rate of the circulation system by adjusting the speed of a variable speed pump motor as hydraulic resistance changes.

Abstract: A closed loop fluid cooling system for marine motors is described. The system includes a motor cooling circuit in fluidic communication with fluid cooling jackets about a motor. The system includes a heat dissipation circuit. The motor cooling circuit is in closed fluidic communication with the heat dissipation circuit. A cooling fluid variably circulates between the motor cooling circuit and the heat dissipation circuit. A heat dissipation member is in fluidic communication with the heat dissipation circuit to receive the circulating cooling fluid, and the heat dissipation member is submerged in the body of water in which the boat is traveling to transfer heat from the cooling fluid to the body of water. A temperature control valve is in fluidic communication with the motor cooling circuit and the heat dissipation circuit.

Abstract: Described are vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from Plasmodium falciparum and purified recombinant protein vaccines such as RTS,S, in the context of appropriate adjuvants.

Abstract: The invention relates to use of an antigen derived from the circumsporozoite protein (CS) protein of Plasmodium falciparum which is expressed at the pre-erythrocytic stage of malarial infection in combination with a pharmaceutically acceptable adjuvant, in the manufacture of a medicament for vaccinating infants against malaria.

Abstract: The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. Furthermore, particles with the specific ratio can be prepared by employing yeast, Saccharomyces cerevisiae or Pichia pastoris. In particular it relates to an immunogenic protein particle comprising the following monomers: a. a fusion protein comprising sequences derived from a CS protein of P. vivax and the S antigen of Hepatitis B (CSV-S), and b. S antigen derived from Hepatitis B virus, and characterised in that the ratio of S to CSV-S is in the range 0.1 to 1. Suitably, the ratio of S to CSV-S is in the range 0.19 to 0.30 or 0.68 to 0.80.

Abstract: The invention relates to a replication deficient simian adenoviral vector C7 encoding a protein comprising CS protein from P. falciparum or a fragment thereof, for example as shown in Seq ID No: 1 or Seq ID No: 3. The invention also relates to processes of preparing said viral vector and use of the viral vector in the treatment/prevention of malaria infection. Compositions, vaccines and kits comprising said viral vector are also described. In one aspect the invention employs a synthetic C7 viral vector. The C7 viral vector according to the invention may be co-administered or co-formulated with a malaria antigen such as RTS,S optionally in the presence of an adjuvant for example comprising 3D-MPL and/or a saponin such as QS21.

Abstract: The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. In particular it relates to an immunogenic protein particle comprising the following monomers: a. a fusion protein comprising sequences derived from a CS protein of P. vivax and the S antigen of Hepatitis B (CSV-S), and b. a fusion protein comprising sequences derived from CS protein of P. falciparum and S antigen of Hepatitis B (RTS), and c. optionally the S antigen derived from Hepatitis B.

Abstract: The present invention relates to a novel hybrid/fusion protein derived from the CS protein of Plasmodium vivax (P. vivax), methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, for example those caused by P. vivax, compositions/vaccines containing the protein or antibodies against the protein such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. The invention also extends to lipoprotein particles of said hybrid protein and formulations/vaccines comprising the same and use thereof. In particular it relates to an immunogenic hybrid fusion protein comprising: a. at least one repeat unit derived from the repeating region of a type I circumsporozoite protein of P. vivax, b. at least one repeat unit derived from the repeating region of a type II circumsporozoite protein of P. vivax, and surface antigen S derived from Hepatitis B virus, or a fragment thereof.

Abstract: Described are vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from Plasmodium falciparum and purified recombinant protein vaccines such as RTS,S, in the context of appropriate adjuvants.

Abstract: A closed loop fluid cooling system for marine motors is described. The system includes a motor cooling circuit in fluidic communication with fluid cooling jackets about a motor. The system includes a heat dissipation circuit. The motor cooling circuit is in closed fluidic communication with the heat dissipation circuit. A cooling fluid variably circulates between the motor cooling circuit and the heat dissipation circuit. A heat dissipation member is in fluidic communication with the heat dissipation circuit to receive the circulating cooling fluid, and the heat dissipation member is submerged in the body of water in which the boat is traveling to transfer heat from the cooling fluid to the body of water. A temperature control valve is in fluidic communication with the motor cooling circuit and the heat dissipation circuit.

Abstract: There is provided, inter alia, a method for the prophylaxis of productive malaria infection in travelers to endemic regions comprising the administration of suitable amounts of a formulation comprising a Plasmodium antigen or an immunogenic fragment or derivative thereof and an adjuvant, comprising a lipid A derivative and a saponin in a liposome formulation.

Abstract: The invention relates to novel vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from Plasmodium falciparum and purified recombinant protein vaccines such as RTS,S, in the context of appropriate adjuvants.